Target distribution of magnetic albumin nanoparticles containing adriamycin in transplanted rat liver cancer model

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 3, 2004, Pages 365-368

  Gong, Lian Sheng ^a   Zhang, Yang De ^a   Liu, Su ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Magnetic albumin nanoparticles; Magnetic target therapy; Transplanted liver cancer model

Indexed keywords

ALBUMIN; DOXORUBICIN; IODINE 125; NANOPARTICLE;

ABDOMINAL SURGERY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG TARGETING; HEART; HEPATIC ARTERY; KIDNEY; LIVER; LIVER CANCER; LIVER GRAFT; LUNG; MAGNETIC FIELD; MALE; NONHUMAN; RADIOACTIVITY; RAT; SMALL INTESTINE; SPLEEN; STOMACH; SURGICAL TECHNIQUE;

ALBUMINS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA 256, WALKER; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; DOXORUBICIN; ELECTROMAGNETIC FIELDS; HEPATIC ARTERY; LIVER NEOPLASMS; MAGNETICS; MALE; NEOPLASM TRANSPLANTATION; PARTICLE SIZE; RATS; RATS, WISTAR;

EID: 4444271713     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Dusheiko GM, Hobbs KEF, Dick R, Burroughs AK. Treatment of small hepatocellular carcinomas. Lancet 1992;340:285-288.
2. Jievaltas M, Stoskuviene L, Petrenkiene V, Barauskas G, Pundzius J. Results of treatment of primary liver cancer at Kaunas University of Medicine Hospital. Medicina (Kaunas) 2004; 40:127-134.
3. Frilling A, Fruhauf N, Sotiropoulos GC, Cicinnati V, Malago M, Broelsch CE. Surgical therapy of hepatocellular carcinoma. Zentralbl Chir 2003;128:900-905.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
5. Editorial: lipiodol computed tomography for small hepatocellular carcinomas. Lancet 1991;337:333-334.
6. Benmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. The prognosis for patients with hepatic matastases from colonic and rectal carcinoma by laparotomy. Cancer (Phila. ) 1970;23:198-202.
7. Chen XP, Qiu FZ, Wu ZD, Zhang BX. Chinese experience with hepatectomy for huge hepatocellular carcinoma. Br J Surg 2004;91:322-326.
8. Beppu T, Ohara C, Yamaguchi Y, Ichihara T, Yamanaka T, Katafuchi S, et al. A new chemoembolization therapy for unresectabled hepatocellular carcinoma using aclarubicin microspheres in combination with cispltin suspended in lipiodol. Reg Cancer Treat 1992;5:33-35.
9. Malt RA. Surgery for hepatic neoplasms. N Engl J Med 1988; 313:1591-1596.
10. Nagano H, Sakon M, Monden M. The chemotherapy for hepatocellular carcinoma. Gan To Kagaku Ryoho 2003;30:1895-1900.
11. Guthoffl, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res 2003; 23:5203-5208.
12. Mancuso A, Giuliani R, Accettura C, Palma M, D'Auria G, Cecere F, et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 2003;23:1917-1922.
13. Lu CD. Blood supply of hepatic neoplasm. Foreign Med Sci Oncol Sect 1991;18:19-22.
14. Goldstein HM, Wallace S, Anderson JH, Bree RL, Gianturco C. Transcatheter occlusion of abdominal tumors. Radiology 1976;120:539-545.
15. Furuse J, Ishii H, Satake M, Onaya H, Nose H, Mikami S, et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am J Clin Oncol 2003;26:159-164.
16. Sarfaraz M, Kennedy AS, Cao ZJ, Sackett GD, Yu CX, Lodge MA, et al. Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors. Med Phys 2003;30: 199-203.
17. Qian J, Truebenbach J, Graepler F, Pereira P, Huppert P, Eul T, et al. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J Gastroenterol 2003;9:94-98.
18. Takeuchi I, Ishida H, Kuwabara K, Hashimoto D, Osada H, Kashimada A, et al. Audit of the safety of hepatic arterial infusion of degradable starch nucrospheres (DSM). Adriamycin (ADM). mitomycin C (MMC) on aged patients with liver metastases of colorectal cancer. Gan To Kagaku Ryoho 2002; 29:2374-2376.
19. Osuga K, Khankan AA, Hori S, Okada A, Sugiura T, Maeda M, et al. Transarterial embolization for large hepatocellular carcinoma with use of superabsorbent polymer microspheres: initial experience. J Vasc Interv Radiol 2002;13:929-934.
20. Amura T, Fujita F, Tanimoto M, Koike M, Suzuki A, Fujita M, et al. Anti-tumor effect of intraperitoneal administration of cisplatin-loaded microspheres to human tumor xenografted nude mice. J Control Release 2002;80:295-307.
21. Liu L, Jiang Z, Teng GJ, Song JZ, Zhang DS, Guo QM, et al. Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma. World J Gastroenterol 1999;5:492-505.
22. Diamandidou E, Ajani JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, et al. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. Am J Roentgenol 1998;170:339-344.
23. Wang Y. Cisplatin (CDDP) microcapsules in transcatheter hepatic arterial chemoembolization of primary liver cancer. Zhonghua Wai Ke Za Zhi 1992;30:337-341,381-382.
24. Wang Y, Wu MC, Zhang XH. Hepatic arterial chemoembolization with CDDP microcapsules. Experimental studies. Chin Med J 1992;105:120-125.
25. Nakasaki H, Hanaue H, Yasuda S, Fujii K, Tajima T, Mitomi T, et al. Inhibitory effect of simultaneous intraportal administration of fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis of colon cancer. Tokai J Exp Clin Med 1994;19:83-91.
26. Roos G, Christensson PI, el Hag IA, Jakobsson B, Teder H, Stenram U. Degradable starch microspheres in cytostatic treatment of a liver carcinoma: experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSV-1069. Anticancer Res 1993;13:635-641.
27. Codde JP, Lusden AJ, Napoli S, Burton MA, Gray BN. A comparative study of the anticancer efficacy of doxorubicin carrying microspheres and liposomes using a rat liver tumor model. Anticancer Res 1993;13:539-543.
28. Verrij RR, Smolders IJ, Bosnie N, Begg AC. Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide. Cancer Res 1992;52:6653-6656.
29. Widder KJ, Morino PA, Morris RM, Howard DP, Poore GA, Senyei AE. Selective targeting of magnetic albumin microspheres to the Yoshida Sarcoma: ultrastructural evaluation of microsphere disposition. Eur J Cancer Clin Oncol 1983;19: 141-147.
30. Ensminger WD, Gyves JW. Regional cancer chemotherapy. Cancer Treat Rep 1984;68:101-105.
31. Zhang YD, Gong LS. The target distribution of magnetic albumin nanoparticles containing adriamycin in normal rat liver. Chin J Mod Med 2001;11:4-7.